tranexamic acid and Cardiovascular Diseases studies

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in total knee arthroplasty (TKA)."	2.84	Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial. ( Aoina, J; Hill, AG; Munro, JT; Poutawera, V; Stowers, MDJ; Vane, A, 2017)
" It was concluded that patients on oral anticoagulants can undergo oral surgery within the therapeutic range without reducing the dosage of anticoagulants, provided that local antifibrinolytic treatment with tranexamic acid solution is instituted."	2.67	Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. ( Alander, U; Blombäck, M; Hall, G; Ramström, G; Sindet-Pedersen, S, 1993)
"0, was employed to analyze demographics including surgical traits, blood loss, drainage, length of hospital stays (LOS), blood biochemical indices, prethrombotic state molecular markers, coagulation function, and adverse events."	1.62	Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery. ( Cai, T; Chen, D; Feng, X; Shi, P; Wang, J; Wang, S; Wang, Y; Zhang, L; Zhang, W, 2021)

Research

Studies (12)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Blood Loss

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	3 (25.00)	29.6817
2010's	6 (50.00)	24.3611
2020's	2 (16.67)	2.80

Authors	Studies
Qiu, J	1
Sun, X	1
Zhang, W	2
Ke, X	1
Yang, G	1
Zhang, L	2
Ashkenazi, I	1
Schermann, H	1
Gold, A	1
Gurel, R	1
Chechik, O	1
Warschawski, Y	1
Schwarzkopf, R	1
Snir, N	1
Shi, P	1
Wang, J	1
Cai, T	1
Chen, D	1
Wang, S	1
Feng, X	1
Wang, Y	1
Stowers, MDJ	1
Aoina, J	1
Vane, A	1
Poutawera, V	1
Hill, AG	1
Munro, JT	1
Dastrup, A	1
Pottegård, A	1
Hallas, J	1
Overgaard, S	1
Ayers, DC	1
Soares, EC	1
Costa, FW	1
Bezerra, TP	1
Nogueira, CB	1
de Barros Silva, PG	1
Batista, SH	1
Sousa, FB	1
Sá Roriz Fonteles, C	1
Later, AF	1
Sitniakowsky, LS	1
van Hilten, JA	1
van de Watering, L	1
Brand, A	1
Smit, NP	1
Klautz, RJ	1
Keiani Motlagh, K	1
Loeb, I	1
Legrand, W	1
Daelemans, P	1
Van Reck, J	1
Mangano, DT	1
Tudor, IC	1
Dietzel, C	1
Sacco, R	1
Sacco, M	1
Carpenedo, M	1
Moia, M	1
Ramström, G	1
Sindet-Pedersen, S	1
Hall, G	1
Blombäck, M	1
Alander, U	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial[NCT05325671]		120 participants (Anticipated)	Interventional	2022-04-05	Not yet recruiting
Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263]	Phase 4	150 participants (Actual)	Interventional	2014-12-31	Completed
Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114]		71 participants (Actual)	Interventional	2016-03-31	Completed
The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816]		25 participants (Actual)	Interventional	2016-04-30	Terminated (stopped due to Study enrollment and goals unable to be reached.)
Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial[NCT02598271]		200 participants (Actual)	Observational	2016-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3

Length of Stay (LOS)

Intervention	mls (Mean)
Control	1090
Intraarticular	716
Systemic	746

Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days

Number of Participants Receiving Allogenic Blood Transfusion

Intervention	days (Median)
Control	4
Topical	4
Systemic	4

"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days

Perioperative Fluid Administration

Intervention	Participants (Count of Participants)
Control	2
Topical	1
Systemic	0

Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1

Number of Participants Experiencing Symptomatic Venothromboembolic (VTE) Disease

Intervention	mls (Mean)
Control	1765
Topical	1613
Systemic	1807

Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery

Range of Active Flexion

Intervention	Participants (Count of Participants)
	DVT	PE
Control	0	0
Systemic	0	1
Topical	0	2

Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3

Range of Passive Flexion

Intervention	degrees (Mean)
	Day 1	Day 2	Day 3
Control	57	71	75
Systemic	58	72	78
Topical	65	75	82

Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3

Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion

Intervention	degrees (Mean)
	Day 1	Day 2	Day 3
Control	65	76	82
Systemic	68	80	87
Topical	74	81	87

To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge

Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury

Intervention	Patients with 1 or more transfusions (Number)
Tranexamic Acid	2
Placebo	3

To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge

Intraoperative Blood Loss in mL

Intervention	Days (Median)
Tranexamic Acid	23
Placebo	9

To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes

Article	Year
Effect of topical tranexamic acid in total hip arthroplasty patients who receive continuous aspirin for prevention of cardiovascular or cerebrovascular events: A prospective randomized study. Orthopaedics & traumatology, surgery & research : OTSR, 2019, Volume: 105, Issue:7 Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement	2019
Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial. The Journal of arthroplasty, 2017, Volume: 32, Issue:11 Topics: Aged; Anesthetics; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; C	2017
Postoperative hemostatic efficacy of gauze soaked in tranexamic acid, fibrin sponge, and dry gauze compression following dental extractions in anticoagulated patients with cardiovascular disease: a prospective, randomized study. Oral and maxillofacial surgery, 2015, Volume: 19, Issue:2 Topics: Administration, Topical; Adult; Aged; Anticoagulants; Brazil; Cardiovascular Diseases; Female; Fibri	2015
Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. The Journal of thoracic and cardiovascular surgery, 2013, Volume: 145, Issue:6 Topics: Aged; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Cardiovascular Diseases; Case	2013
[Prevention of postoperative bleeding in patients taking oral anticoagulants. Effects of tranexamic acid]. Revue de stomatologie et de chirurgie maxillo-faciale, 2003, Volume: 104, Issue:2 Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolyti	2003
Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cardiovascular Diseases; Cellulose, O	2006
Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1993, Volume: 51, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cardiovascular Diseases; Denta	1993

Article	Year
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients? Archives of orthopaedic and trauma surgery, 2020, Volume: 140, Issue:12 Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los	2020
Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery. World neurosurgery, 2021, Volume: 151 Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiovascular Disease	2021
Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death After Total Hip Arthroplasty: A Population-Based Cohort Study from National Danish Databases. The Journal of bone and joint surgery. American volume, 2018, Oct-17, Volume: 100, Issue:20 Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Cardiovascular Diseases; Cohort Studi	2018
Tranexamic Acid: Both Efficacious and Safe When Used in Total Hip Arthroplasty to Reduce Blood Transfusions: Commentary on an article by Alexander Dastrup, MD, et al.: "Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death Aft The Journal of bone and joint surgery. American volume, 2018, 10-17, Volume: 100, Issue:20 Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Cardiovascular Diseases;	2018
The risk associated with aprotinin in cardiac surgery. The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4 Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr	2006
The risk associated with aprotinin in cardiac surgery. The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4 Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr	2006
The risk associated with aprotinin in cardiac surgery. The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4 Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr	2006
The risk associated with aprotinin in cardiac surgery. The New England journal of medicine, 2006, Jan-26, Volume: 354, Issue:4 Topics: Adult; Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Pr	2006

tranexamic acid and Cardiovascular Diseases